Tablets 0,25 mg;
0,5 mg;
Tablets 1 mg
ATC N05B A12
Prescription-only medicine
Reimburse by Health Insurance Fund


Treatment should be as short as possible. It is recommended that the patient be reassessed at the end of no longer than 4 weeks’ treatment and the need for continued treatment established, especially in case the patient is symptom-free. The overall duration of treatment should not be more than 8-12 weeks, including a tapering off process.

In certain cases, extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient’s status with special expertise. As with all benzodiazepines, physicians should be aware that long-term use might lead to dependence in certain patients.

The optimum dosage of alprazolam should be based upon the severity of the symptoms and individual patient response. The lowest dose which can control symptoms should be used. Dosage should be reassessed at intervals of no more than 4 weeks. The usual dosage is stated below; in the few patients who require higher doses, the dosage should be increased cautiously to avoid adverse effects. When higher dosage is required, the evening dose should be increased before the daytime doses. In general, patients who have not previously received psychotropic medications will require lower doses than those so treated, or those with a history of chronic alcoholism.

Treatment should always be tapered off gradually. During the discontinuation of alprazolam treatment, the dosage should be reduced slowly in keeping with good medical practice. It is suggested that the daily dosage of alprazolam be decreased by no more than 0.5 mg every three days. Some patients may require an even slower dosage reduction.
There is reduced clearance of the drug and, as with other benzodiazepines, increased sensitivity to the drug in elderly patients.

Anxiety: 250 micrograms (0.25 mg) to 500 micrograms (0.5 mg) three times daily increasing if required to a total of 3 mg daily.

Geriatric patients or in the presence of debilitating disease: 250 micrograms (0.25 mg) two to three times daily to be gradually increased if needed and tolerated.

Paediatric patients: Safety and efficacy of alprazolam have not been established in children and adolescents below the age of 18 years; therefore the use of alprazolam is not recommended.

If side-effects occur, the dose should be lowered. It is advisable to review treatment regularly and to discontinue use as soon as possible. Should longer-term treatment be necessary, then intermittent treatment may be considered to minimize the risk of dependence.

Medicine’s information on this web page is only a short description of its characteristics. Do not take them as recommendations for self-treatment of your health condition.

You must inform your physician and pharmacist and follow their recommendations before you use the medicine for treatment. Always read carefully the patient information leaflet.

Categories: ,


Each tablet contains 0.25 mg alprazolam.
Each tablet contains 0.5 mg alprazolam.
Each tablet contains 1 mg alprazolam


Alprazolam is indicated for the short-term treatment of moderate or severe anxiety states and anxiety associated with depression. It is only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.
Alprazolam should not be used to treat short-term mild anxiety, such as anxiety or tension associated with the stress of everyday life. As the efficacy of Alprazolam in depression and in phobic or obsessional states has yet to be established, specific treatment may have to be considered.


Alprazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, alprazolam, or to any component of the medicine.
Benzodiazepines are also contraindicated in patients with myasthenia gravis, severe respiratory insufficiency, sleep apnoea syndrome, severe hepatic insufficiency.


Box of 30 tablets of 0.25 mg in a blister package.
Box of 30 tablets of 0.5 mg in a blister package.
Box of 30 tablets of 1 mg in a blister package.